NAFLD fibrosis score was estimated using the formula: NAFLD fibrosis score = -1.675 + 0.037 × age (year) + 0.094 × BMI (kg/m2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet count (×109/L) - 0.66 × albumin (g/dl). NAFLD fibrosis score identified 1289 (29%) at a high risk of advanced liver fibrosis (NAFLD fibrosis score > 0.675). We also evaluated whether these non-invasive biomarkers of hepatic steatosis and fibrosis predict the risk of cardiovascular, kidney and mortality outcomes, and assessed the effect of canagliflozin on clinical outcomes across different levels of steatosis and fibrosis risk. Keywords: cardiovascular disease; clinical trial; diabetic nephropathy; fatty liver disease EN cardiovascular disease clinical trial diabetic nephropathy fatty liver disease 1413 1418 6 04/04/23 20230501 NES 230501 BACKGROUND Non-alcoholic fatty liver disease (NAFLD) occurs commonly in people with type 2 diabetes and is associated with the risk of progression to non-alcoholic steatohepatitis (NASH) and liver fibrosis.[1] NAFLD is also associated with incident cardiovascular events and chronic kidney disease (CKD) in people with type 2 diabetes, reflecting common pathways that underpin these cardiometabolic conditions.[2] However, despite this, few therapeutic options are available to treat NAFLD and reduce the risk of advanced liver fibrosis and cirrhosis.[3] Large cardiovascular and kidney outcome trials have shown that sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular events and kidney failure in patients with type 2 diabetes.[[4]] SGLT2 inhibitors also exert favourable effects on metabolic variables including blood glucose, body weight and blood pressure,[6] which are key risk factors for the development and progression of NAFLD. [Extracted from the article]